Marked hemosiderosis in the myelodysplastic syndrome;Ausgepragte hamosiderose bei myelodysplastischem syndrom

Deutsche Medizinische Wochenschrift

Volumn 124, Issue 4, 1999, Pages 79-82

  Klinz, Carsten ^a  

^a Bundeswehrkrankenhaus Hamburg   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ANEMIA; ARTICLE; CASE REPORT; CLINICAL FEATURE; COMORBIDITY; DIABETES MELLITUS; HEART FAILURE; HEMOSIDEROSIS; HEPATOMEGALY; HUMAN; LOW BACK PAIN; MALE; MYELODYSPLASTIC SYNDROME; SKIN DISCOLORATION; TACHYCARDIA; CONGESTIVE HEART FAILURE; ERYTHROCYTE TRANSFUSION; HYPOGONADISM; LUMBAR VERTEBRA; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOPOROSIS;

DEFERIPRONE; IRON CHELATING AGENT; PYRIDONE DERIVATIVE;

AGED; DIABETES MELLITUS, TYPE 2; ERYTHROCYTE TRANSFUSION; HEART FAILURE, CONGESTIVE; HEMOSIDEROSIS; HUMANS; HYPOGONADISM; IRON CHELATING AGENTS; LUMBAR VERTEBRAE; MALE; MYELODYSPLASTIC SYNDROMES; OSTEOPOROSIS; PYRIDONES;

EID: 0033613717     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1024246     Document Type: Article

References (10)

1. 1 Aul, C., A. Heyll: Therapie der myelodysplastischen Syndrome. Dtsch. med. Wschr. 115 (1990), 1842-1850.
2. 2 Cazzola, M., G. Barosi, P. G. Gobbi, R. Invernizzi, A. Ricardi, E. Ascari: Natural history of idiopathic refractory sideroblastic Anemia. Blood 71 (1988), 305-312.
3. 3 Francis, R. M., M. Peacock, J. E. Aaron, P. L. Selby, G. A. Taylor, J. Thompson, D. H. Marshall, A. Horsman: Osteoporosis in hypogonadal men. Role of decreased plasma 1,25-dihydroxyvitamin D, calcium malabsorption, and low bone formation. Bone 7 (1986), 261-268.
4. 4 Gabutti, V., C. Borgna-Pignatti: Clinical manifestations and therapy of transfusional haemosiderosis. Baillièreøs clin. Haemat. 7 (1994), 919-940.
5. 5 Jaeger, M., C. Aul, D. Söhngen, U. Germing, W. Schneider: Sekundäre Hämochromatose bei polytransfundierten Patienten mit myelodysplastischen Syndromen. Beitr. Infusionsther. 30 (1992), 464-468.
6. 6 Kaltwasser, J. P., E. Werner: Diagnosis and clinical evaluation of iron overload. Baillière's clin. Haematol. 2 (1989), 363-389.
7. 7 Kersten, M. J., R. Lange, M. E. P. Smeets, G. Vreugdenhil, K. J. Roozendaal, W. Lameijer, R. Goudsmit: Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1). A Dutch multicenter trial. Ann. Haematol. 73 (1996), 247-252.
8. 8 Nielsen, P., R. Fischer, R. Engelhardt, P. Tondüry, E. E. Gabbe, G. E. Janka: Liver iron stores in patients with secondary haemosiderosis under iron chelation therapy with deferoxamine or deferiprone. Brit. J. Haematol. 91 (1995), 827-833.
9. 9 Powell, L. W., J. W. Halliday: Iron absorption and iron overload. Clin. Gastroenterol. 10 (1981), 707-735.
10. 10 Sher, G. D., N. Beluzzo, S. D. Milone, D. Papadouris, M. Muraca, C. C. MacKenzie, P. Liu, D. M. Templeton, G. M. Brittenham, N. F. Olivieri: The accurate quantitation of total body iron burden. Blood 84 Suppl. 1 (1994), 363 a.